A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40 Hematology & Oncology

Jingtao Chen, Gerard Zurawski, Sandy Zurawski, Zhiqing Wang, Keiko Akagawa, SangKon Oh, Ueno Hideki, Joseph Fay, Jacques Banchereau, Wenru Song, A. Karolina Palucka

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed. MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy. Methods: We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer antigens that can be targeted to dendritic cells (DCs) via CD40. Results: Healthy individuals and MCL patients have a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Cyclin D1-specific T cells secrete IFN-γ. DCs loaded with whole tumor cells or with selected peptides can elicit cyclin D1-specific CD8+ T cells that kill MCL tumor cells. We developed a recombinant vaccine based on targeting cyclin D1 antigen to human DCs via an anti-CD40 mAb. Targeting monocyte-derived human DCs in vitro with anti-CD40-cyclin D1 fusion protein expanded a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Conclusions: This study demonstrated that cyclin D1 represents a good target for immunotherapy and targeting cyclin D1 to DCs provides a new strategy for mantle cell lymphoma vaccine.

Original languageEnglish (US)
Article number35
JournalJournal of Hematology and Oncology
Volume8
Issue number1
DOIs
StatePublished - Dec 12 2015
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Cyclin D1
Hematology
Dendritic Cells
Vaccines
T-Lymphocytes
Synthetic Vaccines
Immunotherapy
Neoplasms
Antigens
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Monocytes
Immunity

Keywords

  • Cyclin D1
  • Dendritic cells
  • Mantle cell lymphoma
  • Tumor antigen
  • Vaccine

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40 Hematology & Oncology. / Chen, Jingtao; Zurawski, Gerard; Zurawski, Sandy; Wang, Zhiqing; Akagawa, Keiko; Oh, SangKon; Hideki, Ueno; Fay, Joseph; Banchereau, Jacques; Song, Wenru; Palucka, A. Karolina.

In: Journal of Hematology and Oncology, Vol. 8, No. 1, 35, 12.12.2015.

Research output: Contribution to journalArticle

Chen, J, Zurawski, G, Zurawski, S, Wang, Z, Akagawa, K, Oh, S, Hideki, U, Fay, J, Banchereau, J, Song, W & Palucka, AK 2015, 'A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40 Hematology & Oncology', Journal of Hematology and Oncology, vol. 8, no. 1, 35. https://doi.org/10.1186/s13045-015-0131-7
Chen, Jingtao ; Zurawski, Gerard ; Zurawski, Sandy ; Wang, Zhiqing ; Akagawa, Keiko ; Oh, SangKon ; Hideki, Ueno ; Fay, Joseph ; Banchereau, Jacques ; Song, Wenru ; Palucka, A. Karolina. / A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40 Hematology & Oncology. In: Journal of Hematology and Oncology. 2015 ; Vol. 8, No. 1.
@article{8de2435b2f9b4372a130574cb154c293,
title = "A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40 Hematology & Oncology",
abstract = "Background: Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed. MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy. Methods: We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer antigens that can be targeted to dendritic cells (DCs) via CD40. Results: Healthy individuals and MCL patients have a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Cyclin D1-specific T cells secrete IFN-γ. DCs loaded with whole tumor cells or with selected peptides can elicit cyclin D1-specific CD8+ T cells that kill MCL tumor cells. We developed a recombinant vaccine based on targeting cyclin D1 antigen to human DCs via an anti-CD40 mAb. Targeting monocyte-derived human DCs in vitro with anti-CD40-cyclin D1 fusion protein expanded a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Conclusions: This study demonstrated that cyclin D1 represents a good target for immunotherapy and targeting cyclin D1 to DCs provides a new strategy for mantle cell lymphoma vaccine.",
keywords = "Cyclin D1, Dendritic cells, Mantle cell lymphoma, Tumor antigen, Vaccine",
author = "Jingtao Chen and Gerard Zurawski and Sandy Zurawski and Zhiqing Wang and Keiko Akagawa and SangKon Oh and Ueno Hideki and Joseph Fay and Jacques Banchereau and Wenru Song and Palucka, {A. Karolina}",
year = "2015",
month = "12",
day = "12",
doi = "10.1186/s13045-015-0131-7",
language = "English (US)",
volume = "8",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40 Hematology & Oncology

AU - Chen, Jingtao

AU - Zurawski, Gerard

AU - Zurawski, Sandy

AU - Wang, Zhiqing

AU - Akagawa, Keiko

AU - Oh, SangKon

AU - Hideki, Ueno

AU - Fay, Joseph

AU - Banchereau, Jacques

AU - Song, Wenru

AU - Palucka, A. Karolina

PY - 2015/12/12

Y1 - 2015/12/12

N2 - Background: Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed. MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy. Methods: We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer antigens that can be targeted to dendritic cells (DCs) via CD40. Results: Healthy individuals and MCL patients have a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Cyclin D1-specific T cells secrete IFN-γ. DCs loaded with whole tumor cells or with selected peptides can elicit cyclin D1-specific CD8+ T cells that kill MCL tumor cells. We developed a recombinant vaccine based on targeting cyclin D1 antigen to human DCs via an anti-CD40 mAb. Targeting monocyte-derived human DCs in vitro with anti-CD40-cyclin D1 fusion protein expanded a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Conclusions: This study demonstrated that cyclin D1 represents a good target for immunotherapy and targeting cyclin D1 to DCs provides a new strategy for mantle cell lymphoma vaccine.

AB - Background: Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed. MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy. Methods: We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer antigens that can be targeted to dendritic cells (DCs) via CD40. Results: Healthy individuals and MCL patients have a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Cyclin D1-specific T cells secrete IFN-γ. DCs loaded with whole tumor cells or with selected peptides can elicit cyclin D1-specific CD8+ T cells that kill MCL tumor cells. We developed a recombinant vaccine based on targeting cyclin D1 antigen to human DCs via an anti-CD40 mAb. Targeting monocyte-derived human DCs in vitro with anti-CD40-cyclin D1 fusion protein expanded a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Conclusions: This study demonstrated that cyclin D1 represents a good target for immunotherapy and targeting cyclin D1 to DCs provides a new strategy for mantle cell lymphoma vaccine.

KW - Cyclin D1

KW - Dendritic cells

KW - Mantle cell lymphoma

KW - Tumor antigen

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85018115359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018115359&partnerID=8YFLogxK

U2 - 10.1186/s13045-015-0131-7

DO - 10.1186/s13045-015-0131-7

M3 - Article

C2 - 25888530

AN - SCOPUS:85018115359

VL - 8

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 35

ER -